Dr Stephen Ryder

Queens Medical Centre Campus, Derby Road, Nottingham, NG7 2UH

stephen.ryder@nuh.nhs.uk View full bio

Consultant Physician in Hepatology and Gastroenterology

Title	Start Date	Status
Does addition of metformin to standard combination therapy increase sustained response rates for pat	1st August 2011	Ended
A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, an	21st May 2018	Active
An open label single arm study to investigate the safety and efficacy of multiple administartions of	1st September 2011	Ended
A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week t	10th July 2018	Active
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT)	2nd March 2017
IL-1 Signal Inhibition in Alcoholic Hepatitis	28th May 2019	Active
A phase I, randomised, double-blind, placebo-controlled, multi-centre, ascending-dose trial to evalu	1st May 2016	Active

Title
Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic
Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiv
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis i
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primar
An analysis of rebleeding rates for variceal haemorrhage at a regional centre: what is the applicabi
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary
In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholan
Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute varice
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widesprea
ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirr
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treat
Fast-food hyper-alimentation and exercise restriction in healthy subjects
Prediction of liver disease in patients whose liver function tests have been checked in primary care
Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal
Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom populati
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile
Chronic hepatitis C - what do the new drugs offer and who should get them first?
The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patie
Effectiveness of a nurse-led alcohol liaison service in a secondary care medical unit
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steat
The Road to a Successful Transjugular Intrahepatic Portosystemic Shunt (Tips) Service: Experience of
Screening for hepatocellular carcinoma: patient selection and perspectives
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Current op
The hepatitis C revolution part 1: antiviral treatment options
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis i